N-4-Nitrobenzyl-beta-alanine was reacted with alkyl/arylsulfonyl halides, f
ollowed by conversion of the COOH to the CONHOH group. Structurally related
compounds were obtained by reaction of N-4-nitrobenzyl-beta-alanine with a
ryl isocyanates, arylsulfonyl isocyanates or benzoyl isothiocyanate, follow
ed by similar conversion of the COOH into the CONHOH moiety. Another subser
ies of derivatives was prepared from sulfanilyl- or metanilyl-4-nitrobenzyl
-beta-alanine by reaction with arylsulfonyl isocyanates, followed by the in
troduction of the hydroxamate moiety. The new compounds were assayed as inh
ibitors of four matrix metalloproteinases (MMPs), MMP-1, MMP-2, MMP-8 and M
MP-9, and of the Clostridium histolyticum collagenase (ChC). Some of the pr
epared hydroxamate derivatives proved to be very effective collagenase/gela
tinase inhibitors, depending on the substitution pattern at the sulfonamido
moiety. Substitutions leading to the best inhibitors of MMP-1, a short-poc
ket enzyme, were those involving pentafluorophenylsulfonyl or 3-trifluorome
thyl-phenylsulfonyl at P-1' (K-I of 3-5 nM). For MMP-2, MMP-8 and MMP-9 (de
ep-pocket enzymes), the best inhibitors were those containing perfluoroalky
lsulfonyl- and substituted-arylsulfonyl moieties, such as pentafluorophenyl
sulfonyl, 3- and 4-protected-aminophenylsulfonyl-, 3- and 4-carboxy-phenyls
ulfonyl-, arylsulfonylureido- or arylsulfonylureido-sulfanilyl-/metanilyl m
oieties at P-1'. Bulkier groups in this position, such as 1- and 2-naphthyl
-, substituted-naphthyl or quinoline-8-yl- moieties, among others, led to l
ess effective MMP/ChC inhibitors. The best ChC inhibitors were again those
containing pentafluorophenylsulfonyl, 3- and 4-protected-aminophenylsulfony
l P-1. groups. This study demonstrates that the 4-nitrobenzyl moiety, inves
tigated here for the first time, is an efficient P-2' anchoring moiety, whe
reas the beta-alanyl scaffold can successfully replace the alpha-amino acyl
one, for obtaining potent MMP/ChC inhibitors. (C) 2000 Elsevier Science B.
V. All rights reserved.